scholarly journals Prognostic values of left ventricular mass index in chronic kidney disease patients

2020 ◽  
Vol 35 (12) ◽  
pp. 2203-2203
Author(s):  
Giovanni Tripepi ◽  
Graziella D’Arrigo ◽  
Francesca Mallamaci ◽  
Gerard London ◽  
Navdeep Tangri ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Left Ventricular Mass ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
Ventricular Mass Index ◽  
Ventricular Mass

Ferrokinetics is associated with the left ventricular mass index in patients with chronic kidney disease

2017 ◽  
Vol 72 (4) ◽  
pp. 460-466 ◽  
Author(s):  
Akihito Tanaka ◽  
Daijo Inaguma ◽  
Yu Watanabe ◽  
Eri Ito ◽  
Naoki Kamegai ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Left Ventricular Mass ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
Ventricular Mass Index ◽  
Ventricular Mass

Prognostic values of left ventricular mass index in chronic kidney disease patients

2019 ◽  
Author(s):  
Giovanni Tripepi ◽  
Graziella D’Arrigo ◽  
Francesca Mallamaci ◽  
Gerard London ◽  
Navdeep Tangri ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Left Ventricular Mass ◽  
Left Ventricular Mass Index ◽  
De Novo ◽  
Left Ventricular ◽  
Ventricular Mass Index ◽  
Risk Of Death ◽  
Sharp Score ◽  
Ventricular Mass

Abstract Background Left ventricular hypertrophy is causally implicated in the high risk of death and heart failure (HF) in chronic kidney disease (CKD) patients. Whether the left ventricular mass index (LVMI) adds meaningful predictive power for mortality and de novo HF to simple risk models has not been tested in the CKD population. Methods We investigated this problem in 1352 CKD patients enrolled in the Chronic Renal Insufficiency Cohort (CRIC). LVMI was measured by echocardiography and the risks for death and HF were estimated by the Study of Heart and Renal Protection (SHARP) score, a well-validated risk score in CKD patients. Results During a median follow-up of 7.7 years, 326 patients died and 208 had de novo HF. The LVMI and the SHARP score and a cross-validated model for HF (CRIC model) were all significantly (P < 0.001) related to the risk of death and HF. LVMI showed a discriminatory power for death (Harrell’s C index 66%) inferior to that of the SHARP score (71%) and the same was true for the risk of HF both in the test (LVMI 72%, CRIC model 79%) and in the validation cohort (LVMI 71%, CRIC model 74%). LVMI increased very little the discriminatory (2–3%) and the risk reclassification power (3.0–4.8%) by the SHARP score and the CRIC model for HF for the same outcomes. Conclusions In CKD, measurement of LVMI solely for the stratification of risk of death and perhaps for the risk of HF does not provide evident prognostic values in this condition.

Sign in / Sign up

Export Citation Format

Share Document